Log in

NASDAQ:BMRNBioMarin Pharmaceutical Stock Price, Forecast & News

$106.55
+0.95 (+0.90 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$103.69
Now: $106.55
$107.11
50-Day Range
$79.55
MA: $92.28
$106.70
52-Week Range
$62.88
Now: $106.55
$109.51
Volume2.36 million shs
Average Volume1.63 million shs
Market Capitalization$19.27 billion
P/E Ratio174.67
Dividend YieldN/A
Beta1.01
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Read More
BioMarin Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.70 billion
Cash Flow$0.64 per share
Book Value$17.92 per share

Profitability

Net Income$-23,850,000.00

Miscellaneous

Employees3,001
Market Cap$19.27 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

How has BioMarin Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BMRN stock has increased by 22.6% and is now trading at $106.55. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioMarin Pharmaceutical?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 5 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioMarin Pharmaceutical.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for BioMarin Pharmaceutical.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Wednesday, April, 29th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.32. The biotechnology company had revenue of $502.07 million for the quarter, compared to analyst estimates of $468.77 million. BioMarin Pharmaceutical had a net margin of 6.31% and a return on equity of 3.62%. BioMarin Pharmaceutical's revenue for the quarter was up 25.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.32) EPS. View BioMarin Pharmaceutical's earnings history.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.85-1.95 billion, compared to the consensus revenue estimate of $1.97 billion.

What price target have analysts set for BMRN?

22 brokerages have issued 12-month price objectives for BioMarin Pharmaceutical's stock. Their forecasts range from $77.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $112.25 in the next year. This suggests a possible upside of 5.3% from the stock's current price. View analysts' price targets for BioMarin Pharmaceutical.

Has BioMarin Pharmaceutical been receiving favorable news coverage?

News headlines about BMRN stock have been trending extremely negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutBioMarin Pharmaceutical.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
  • Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital Research Global Investors (12.19%), Primecap Management Co. CA (9.85%), Jennison Associates LLC (4.54%), Clearbridge Investments LLC (3.49%), Geode Capital Management LLC (1.15%) and Nuveen Asset Management LLC (1.01%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View institutional ownership trends for BioMarin Pharmaceutical.

Which institutional investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, KBC Group NV, Two Sigma Advisers LP, USS Investment Management Ltd, PointState Capital LP, Balyasny Asset Management LLC, Squarepoint Ops LLC, and Sofinnova Investments Inc.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, and V Bryan Lawlis. View insider buying and selling activity for BioMarin Pharmaceutical.

Which institutional investors are buying BioMarin Pharmaceutical stock?

BMRN stock was acquired by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Jennison Associates LLC, Janus Henderson Group PLC, Nuveen Asset Management LLC, Orbimed Advisors LLC, Eagle Asset Management Inc., Pictet Asset Management Ltd., and Carillon Tower Advisers Inc.. View insider buying and selling activity for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $106.55.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $19.27 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. BioMarin Pharmaceutical employs 3,001 workers across the globe.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is www.bmrn.com.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.